| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2021-02-12 | New Enterprise Associates 15, L.P. | Inozyme Pharma, Inc. | 2,437,689 | 10.4% | EDGAR |
| SC 13G | 2021-02-09 | Pivotal bioVenture Partners Fund I, L.P. | Inozyme Pharma, Inc. | 1,591,154 | 6.8% | EDGAR |
| SC 13D/A | 2021-02-01 | Novo Holdings A/S | Inozyme Pharma, Inc. | 2,194,379 | 9.4% | EDGAR |
| SC 13D/A | 2020-10-05 | Novo Holdings A/S | Inozyme Pharma, Inc. | 2,569,379 | 11.0% | EDGAR |
| SC 13D | 2020-08-07 | Longitude Capital Partners III, LLC | Inozyme Pharma, Inc. | 2,819,379 | 12.1% | EDGAR |
| SC 13G | 2020-08-06 | Flynn James E | Inozyme Pharma, Inc. | 1,150,299 | 5.2% | EDGAR |
| SC 13D | 2020-08-04 | Pivotal bioVenture Partners Fund I, L.P. | Inozyme Pharma, Inc. | 1,591,154 | 7.1% | EDGAR |
| SC 13D | 2020-07-29 | Novo Holdings A/S | Inozyme Pharma, Inc. | 2,569,379 | 11.5% | EDGAR |